glp-1 receptor agonists in pediatric and adolescent obesity Oral GLP-1-Based Therapeutics the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, Emerging Strategies Researchers at UC Irvine issue
Description
doi: 10.1139/bcb-2021-0365 43 BudakMachnikGBudakRJabuzekKBodysABelowskiDet al
Nat Med 31 , 745746 (2025)
Dual GLP-1/GIP Agonists: Expanding Incretin-Based Therapy The Role of GIP in Metabolic Regulation Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone secreted by K cells in the small intestine in response to food intake
No GLP-1 receptor agonist is approved for weight management in children under 6
other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies
